HHS & Healthcare Contracts Intelligence — August 07, 2026

Merck Sharp & Dohme LLC received a $155.8 million firm-fixed-price contract from HHS BARDA/ASPR for ERVEBO (Ebola vaccine) procurement, with a total base-plus-options value of $173.6 million over 10 years. This provides Merck with predictable, long-term revenue from a sole-source civilian biodefense program, reinforcing its position in pandemic preparedness.

The firm-fixed-price structure exposes Merck to cost overrun risk if ERVEBO production costs exceed the fixed price, especially over a 10-year period. The contract data does not disclose profitability, margins, or whether pricing includes escalation clauses.

This single contract represents a material civilian award to Merck, but concentration in one HHS program (ERVEBO) creates dependency on sustained government demand for Ebola vaccines, which may fluctuate with outbreak cycles and budget priorities.

The contract was not competed, signaling that Merck holds a unique position as the sole ERVEBO manufacturer for the U.S. government. This sole-source status reduces competitive pressure and supports stable revenue for Merck’s vaccine division.

The 10-year performance period (2024–2034) indicates sustained HHS commitment to biodefense stockpiling, which could lead to follow-on contracts for other vaccines or therapeutics, benefiting Merck and other biopharma firms with pandemic preparedness portfolios.

The $155.8M ERVEBO contract to Merck underscores continued HHS investment in biodefense stockpiles, a civilian priority independent of defense budgets. This theme supports pharmaceutical companies with government vaccine contracts.

{"entity" => "Merck Sharp & Dohme LLC", "reason" => "Awarded $155.8M HHS contract for ERVEBO; execution risk from firm-fixed-price and option exercise timing.", "trigger" => "Option exercise announcements by HHS; quarterly vaccine segment margin reports"}

{"entity" => "HHS BARDA/ASPR", "reason" => "Primary civilian buyer; future procurement decisions affect Merck and broader biodefense sector.", "trigger" => "HHS budget releases; new BARDA/ASPR contract awards for vaccines or therapeutics"}